Compare Merck & Co., Inc. (MRK) vs Ryanair Holdings plc (RYAAY) Price & Performance

Merck & Co., Inc.Trade

Ryanair Holdings plcTrade

Price performance (Past 24H)

Key statistics

Merck & Co., Inc. vs Ryanair Holdings plc — how do they compare? Merck & Co., Inc. trades at $125.97 (market cap $307.25B), while Ryanair Holdings plc trades at $58.99 (market cap $29.31B). The key difference: Merck & Co., Inc. is far larger — about 10.5× Ryanair Holdings plc's market cap, and Merck & Co., Inc. pays the higher dividend (2.73%). Which is the better fit depends on your goals.

	MRK	RYAAY
Market Cap	$307.25B	$29.31B
Sector	Health	Industrials
52-Week High	$129.52	$73.82
52-Week Low	$77.60	$53.24
Enterprise Value	$350.66B	$26.33B
Dividend Yield	2.73%	1.68%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Merck & Co., Inc.

Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.

Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.

Ryanair Holdings plc

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

MRK

Over 180 companies develop 200+ PD-1/PD-L1 inhibitors, reshaping cancer treatment landscape.Delveinsight · 6 hours agoBullish Schwab U.S. Dividend Equity ETF (SCHD) remains a Buy for strong dividends and growth potential.Seeking Alpha · 2 days agoBullish Merck rated Strong Buy on oncology growth and new LIPFENDRA launch for cholesterol controlSeeking Alpha · 4 days agoBullish View details →

RYAAY

US-Iran conflict raises oil prices, worries on economy and stocks' outlook.CNBC · 15 hours agoBearish Ryanair Q2 earnings miss due to fuel cost surge and lower ticket prices amid economic uncertaintyAlex Lavoie · 19 hours agoBearish Ryanair's Q1 profit falls 34% due to rising fuel costs and lower ticket fares amid Middle East tensionsCNBC · 1 day agoBearish View details →

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

About Ryanair Holdings plc

Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.